GlaucomaPhase 3NCT00333125
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study testing Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav) and Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt) in people with Glaucoma and Ocular Hypertension, run by Alcon Research.
Trial summary
The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glaucoma, Ocular Hypertension
- What is being tested?
- Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav) and Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 319 participants
- Where
- No sites listed yet
- Study dates
- Apr 2006to Feb 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 or older.
- Diagnosis of glaucoma or ocular hypertension.
- Other protocol-defined inclusion criteria may apply.
Who cannot join
- Under 18.
- Other protocol-defined exclusion criteria may apply.
About this study
The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.
- Conditions
- Glaucoma, Ocular Hypertension
- Being tested
- Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav), Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt), Timolol Vehicle
- Medical subject headings
- Glaucoma, Ocular Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)Drug
Also called DuoTrav
One drop in the study eye(s) once daily, 9 PM, for 6 weeks
Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)Drug
Also called Cosopt
One drop in the study eye(s) twice daily for 6 weeks
Timolol VehicleOther
One drop in the study eye(s) once daily for 6 weeks
| Study group | Role | What they receive |
|---|---|---|
| Travoprost/Timolol | Experimental | Not described Receives: Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav); Other: Timolol Vehicle |
| Dorzolamide/Timolol | Active comparator | Not described Receives: Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Intra-Ocular Pressure (IOP)
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2006 (estimated)
- Study startApr 2006
- Primary completionFeb 2007
- Study completionFeb 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- More trials run by Alcon ResearchThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 319 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alcon Research
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00333125
- Sponsor's protocol ID
- C-05-25
- Status last verified
- May 2012
- First submitted
- 31 May 2006
- Last updated
- 18 Nov 2016
- Results posted
- No
Publications
Saeed M, Kadir S, Kaufman SL, Murray RR, Milligan F, Cotton PB. Bleeding following endoscopic sphincterotomy: angiographic management by transcatheter embolization. Gastrointest Endosc. 1989 Jul-Aug;35(4):300-3. doi: 10.1016/s0016-5107(89)72796-6.
PubMed 2788589
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
- ClinicalTrials.gov ID
- NCT00333125
- Acronym / sponsor ID
- C-05-25
- Conditions
- Glaucoma, Ocular Hypertension
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 319 participants (actual)
- Lead sponsor
- Alcon ResearchIndustry (pharma, biotech, devices)
- Study start
- Apr 2006
- Primary completion
- Feb 2007 (actual)
- Study completion
- Feb 2007 (actual)
- First posted
- 2 Jun 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Travoprost/Timolol | Experimental | Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav), Other: Timolol Vehicle |
| Dorzolamide/Timolol | Active comparator | Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 18 or older.
- Diagnosis of glaucoma or ocular hypertension.
- Other protocol-defined inclusion criteria may apply.
Key exclusion criteria (2 listed)
- Under 18.
- Other protocol-defined exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)Also: DuoTravOne drop in the study eye(s) once daily, 9 PM, for 6 weeks | Drug | Travoprost/Timolol |
| Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)Also: CosoptOne drop in the study eye(s) twice daily for 6 weeks | Drug | Dorzolamide/Timolol |
| Timolol VehicleOne drop in the study eye(s) once daily for 6 weeks | Other | Travoprost/Timolol |
Primary outcome
Mean Intra-Ocular Pressure (IOP)
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2016.
- Results publication: PubMed 2788589Saeed M, Kadir S, Kaufman SL, Murray RR, Milligan F, Cotton PB. Bleeding following endoscopic sphincterotomy: angiographic management by transcatheter embolization. Gastrointest Endosc. 1989 Jul-Aug;35(4):300-3. doi: 10.1016/s0016-5107(89)72796-6.
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav) and Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt) in people with Glaucoma and Ocular Hypertension, run by Alcon Research.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Intra-Ocular Pressure (IOP) (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00333125, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2016.